A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
NCT ID: NCT01455870
Last Updated: 2016-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
535 participants
INTERVENTIONAL
2013-05-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
NCT01455909
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
NCT02577016
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
NCT02025907
Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
NCT02173457
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
NCT02791490
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ITCA 650 60 mcg/day
ITCA 650 is exenatide in DUROS
ITCA 650 60 mcg/day
exenatide in DUROS
sitagliptin
sitagliptin 100 mg/day
sitagliptin
oral sitagliptin 100 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ITCA 650 60 mcg/day
exenatide in DUROS
sitagliptin
oral sitagliptin 100 mg/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* on metformin monotherapy
* BMI between 25 \& 45 kg/m2
Exclusion Criteria
* history of pancreatitis
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intarcia Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Chandler, Arizona, United States
Long Beach, California, United States
Los Angeles, California, United States
San Diego, California, United States
San Mateo, California, United States
Tustin, California, United States
Valley Village, California, United States
Walnut Creek, California, United States
Boca Raton, Florida, United States
Clearwater, Florida, United States
Coral Gables, Florida, United States
Miami, Florida, United States
North Miami Beach, Florida, United States
Pembroke Pines, Florida, United States
Canton, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Avon, Indiana, United States
Franklin, Indiana, United States
Greenfield, Indiana, United States
Muncie, Indiana, United States
Valparaiso, Indiana, United States
Wichita, Kansas, United States
Wichita, Kansas, United States
Metairie, Louisiana, United States
Brockton, Massachusetts, United States
Traverse City, Michigan, United States
Troy, Michigan, United States
St Louis, Missouri, United States
Billings, Montana, United States
Lincoln, Nebraska, United States
Las Vegas, Nevada, United States
Brooklyn, New York, United States
Endwell, New York, United States
Morehead City, North Carolina, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Kettering, Ohio, United States
Norman, Oklahoma, United States
Bend, Oregon, United States
Uniontown, Pennsylvania, United States
Memphis, Tennessee, United States
Corpus Christi, Texas, United States
Dallas, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Sugar Land, Texas, United States
Tomball, Texas, United States
Rijeka, , Croatia
Hvidovre, , Denmark
Bad Lauterberg im Harz, Lower Saxony, Germany
Riga, , Latvia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ITCA 650-CLP-105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.